Luminopia meets rigorous criteria set by Highmark's New Technology Advisory Committee (NTAC) and receives a positive coverage determination from the plan CAMBRIDGE, Mass. , Aug. 6, 2024 /PRNewswire/ -- Luminopia, Inc.
, a digital health company pioneering a new class of treatments for neuro-visual disorders, announced today that Highmark, who through its subsidiaries and affiliates provides health insurance to 6.9 million members in Pennsylvania , West Virginia , Delaware , and New York , has approved Luminopia's FDA-approved 1 therapy for children with amblyopia for coverage. Highmark follows rigorous criteria through its New Technology Advisory Committee (NTAC) to evaluate clinical evidence and determine the medical necessity of new digital health technologies.
The unmet need left by traditional amblyopia treatments, along with the substantial body of clinical data supporting Luminopia's efficacy and safety, provided the backing for this positive coverage decision by Highmark's NTAC. Luminopia is a dual-acting, binocular therapy for amblyopia, the leading cause of vision loss in children, that allows kids ages 4-7 to watch TV rather than wear an eye patch or use blurring atropine drops. Both eye-patching and atropine drops are monocular treatments that only block vision in the stronger eye and are associated with poor treatment compliance and residual vision deficits in over 50% of patients.
Luminopia's proprietary therapeutic algorithms modify media content and present it .